XERS FY 2024 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$960M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$203M+23.9% YoY

Gross Profit

$166M81.9% margin

Operating Income

-$34M-16.6% margin

Net Income

-$55M-27.0% margin

EPS (Diluted)

$-0.37

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$38M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$323M

Total Liabilities

$353M

Stockholders' Equity

-$30M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$203M	$164M	+23.9%
Gross Profit	$166M	$135M	+22.9%
Operating Income	-$34M	-$44M	+23.5%
Net Income	-$55M	-$62M	+11.9%